Here's a summary of Alivus Life Sciences' latest investor presentation: **1. Financial Highlights:** Alivus reported Q1 FY26 revenue of ₹601.8 Cr, with EBITDA ₹181.3 Cr (30.1% margin) and PAT ₹121.5 Cr.

Gross margin climbed to 55.1%. The company generated a strong ₹100 Cr free cash flow, ending with ₹660.4 Cr cash.

Management anticipates high single-digit revenue growth for FY26, with margins in the 28-30% range. **2. Strategic Initiatives & Growth Drivers:** Ambitious capacity expansion is underway, including greenfield Solapur (Phase 1 construction started for FY26) and brownfield additions at Ankleshwar and Dahej.

These efforts aim to nearly double total reactor capacity by FY28. The R&D pipeline is robust with new synthetic molecules, high-potency APIs, and iron complexes, signaling future growth. **3. Business Developments:** Non-GPL business surged 14.5% YoY, now comprising 75% of total revenue, driven by strong growth in India, Europe, and Japan.

Generic API revenue also grew.

The GPL segment saw a de-growth due to customer inventory rationalization.

CDMO experienced a temporary demand dip, but a 5th project is set for commercialization in H2 FY26. **4. Market Position & Competitive Advantage:** Regulated markets contribute 83% of Q1 revenue, bolstered by Non-GPL strength.

Chronic therapies consistently make up 70% of revenue.

Alivus maintains an extensive global footprint with 569 DMF/CEP filings and a broad customer base, highlighting strong market access and product development capabilities. **5. Investor Implications:** Alivus's Q1 FY26 performance shows resilient profitability and cash generation despite some segmental challenges.

Significant planned capacity expansions and a diverse R&D pipeline indicate strong long-term growth potential.

Investors should monitor continued Non-GPL strength and CDMO recovery as key performance drivers.